← Back to Screener
MindWalk Holdings Corp. Common Stock (HYFT)
Price$1.68
Value ScoreD
Growth ScoreD
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-26.37%
Price vs S&P 500 (4W)32.29%
VGM Score47.20
Market Capitalization$56.40M
All Metrics
Book Value / Share (Quarterly)$0.23
P/TBV (Annual)1.24x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)8.19%
Cash Flow / Share (Quarterly)$-0.18
Price vs S&P 500 (YTD)-15.85%
Gross Margin (TTM)60.32%
Net Profit Margin (TTM)-66.46%
EPS (TTM)$-0.19
10-Day Avg Trading Volume0.61M
EPS Excl Extra (TTM)$-0.19
Revenue Growth (5Y)11.77%
EPS (Annual)$-0.65
ROI (Annual)-81.65%
Gross Margin (Annual)55.25%
Net Profit Margin (5Y Avg)-97.99%
Cash / Share (Quarterly)$0.22
Revenue Growth QoQ (YoY)-32.40%
ROA (Last FY)-68.03%
Revenue Growth TTM (YoY)-23.23%
EBITD / Share (TTM)$-0.19
ROE (5Y Avg)-57.82%
Operating Margin (TTM)-65.58%
Cash Flow / Share (Annual)$-0.11
P/B Ratio7.36x
P/B Ratio (Quarterly)7.09x
Net Income / Employee (Annual)$-213,025
EV / Revenue (TTM)5.36x
Net Interest Coverage (TTM)-38.07x
ROA (TTM)-36.48%
EPS Incl Extra (Annual)$-0.65
Current Ratio (Annual)2.08x
Quick Ratio (Quarterly)3.40x
3-Month Avg Trading Volume0.39M
52-Week Price Return139.32%
Revenue / Employee (TTM)$129,799
Tangible BV / Share (Quarterly)$0.23
P/S Ratio (Annual)4.46x
Asset Turnover (Annual)0.55x
52-Week High$3.25
Operating Margin (5Y Avg)-101.70%
EPS Excl Extra (Annual)$-0.65
CapEx CAGR (5Y)10.37%
26-Week Price Return-18.45%
Quick Ratio (Annual)1.72x
13-Week Price Return43.59%
Total Debt / Equity (Annual)0.57x
Current Ratio (Quarterly)3.74x
Enterprise Value$71.01M
Revenue / Share Growth (5Y)-6.57%
Asset Turnover (TTM)0.55x
Revenue / Employee (Annual)$172,777
Inventory Turnover (Annual)5.18x
Pretax Margin (Annual)-139.75%
Cash / Share (Annual)$0.17
3-Month Return Std Dev98.88%
Gross Margin (5Y Avg)56.30%
Net Income / Employee (TTM)$-86,245
ROE (Last FY)-127.97%
Net Interest Coverage (Annual)-43.42x
EPS Basic Excl Extra (Annual)$-0.65
P/FCF (TTM)122.79x
Receivables Turnover (TTM)4.91x
Total Debt / Equity (Quarterly)0.24x
EPS Incl Extra (TTM)$-0.19
Receivables Turnover (Annual)5.62x
ROI (TTM)-48.39%
P/S Ratio (TTM)5.94x
Pretax Margin (5Y Avg)-101.28%
Revenue / Share (Annual)$0.53
Tangible BV / Share (Annual)$0.35
Price vs S&P 500 (52W)114.95%
Year-to-Date Return-7.69%
5-Day Price Return-3.45%
EPS Normalized (Annual)$-0.65
ROA (5Y Avg)-35.25%
Net Profit Margin (Annual)-123.30%
Month-to-Date Return-4.55%
EBITD / Share (Annual)$-0.68
Operating Margin (Annual)-136.87%
LT Debt / Equity (Annual)0.03x
ROI (5Y Avg)-42.63%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.19
P/TBV (Quarterly)7.09x
P/B Ratio (Annual)1.18x
Inventory Turnover (TTM)6.07x
Pretax Margin (TTM)-71.76%
Book Value / Share (Annual)$0.37
Price vs S&P 500 (13W)35.34%
Beta0.83x
Revenue / Share (TTM)$0.28
ROE (TTM)-63.66%
52-Week Low$0.51
vGradeD
gGradeD
mGradeB
vgmGradeC
Show chart for
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.13
4.13
4.13
4.11
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
HYFTMindWalk Holdings Corp. Common Stock | D | D | B | $1.68 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
MindWalk Holdings Corp is a bio-native AI company that accelerates drug discovery and development using proprietary HYFT technology and its LensAI platform. The company integrates molecular sequence, structure, function, and literature data into a unified computational framework, paired with an internal wet lab for validation. This integrated approach enables rapid applications in epitope mapping, protein design, vaccine exploration, and large-scale biologics analysis, helping to advance drug candidates faster from discovery to validation.